Literature DB >> 7527086

Resistance to nucleoside analogs of selective mutants of human immunodeficiency virus type 2 reverse transcriptase.

M Perach1, T Rubinek, A Hizi.   

Abstract

We have studied selected mutants of human immunodeficiency virus type 2 (HIV-2) reverse transcriptase (RT) in a cell-free system in order to assess whether the mutant proteins exhibit a reduction in the sensitivity to nucleoside analog inhibitors similar to that of HIV-1 RT. We have modified, by site-directed mutagenesis, several of those amino acid residues so that their equivalent substitutions in HIV-1 RT have led to the formation of HIV-1 RT variants with the highest degree of resistance to dideoxynucleoside triphosphates (i.e., Glu-89-->Gly, Leu-74-->Val, and Ser-215-->Tyr [which is comparable to the Thr-215-->Tyr mutation of HIV-1 RT] and the double mutations Glu-89-->Gly/Ser-215-->Tyr and and Leu-74-->Val/Ser-215-->Tyr). The similarity found between resistance of the newly generated HIV-2 RT mutants to nucleoside analogs and that of the comparable mutants of HIV-1 RT can support the notion that the overall protein folding around the DNA polymerase active site in HIV-2 RT is quite similar to that of HIV-1 RT.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7527086      PMCID: PMC188600     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

Review 1.  HIV resistance to reverse transcriptase inhibitors.

Authors:  E De Clercq
Journal:  Biochem Pharmacol       Date:  1994-01-20       Impact factor: 5.858

2.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

3.  pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

Authors:  J J Eron; Y K Chow; A M Caliendo; J Videler; K M Devore; T P Cooley; H A Liebman; J C Kaplan; M S Hirsch; R T D'Aquila
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

4.  Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate.

Authors:  S S Carroll; J Geib; D B Olsen; M Stahlhut; J A Shafer; L C Kuo
Journal:  Biochemistry       Date:  1994-03-01       Impact factor: 3.162

5.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

Review 6.  Population migration and the spread of types 1 and 2 human immunodeficiency viruses.

Authors:  T C Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

7.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

Authors:  P L Boyer; C Tantillo; A Jacobo-Molina; R G Nanni; J Ding; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistance.

Authors:  S F Lacey; B A Larder
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

9.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  4 in total

1.  Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors:  B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.

Authors:  J Ren; R M Esnouf; A L Hopkins; E Y Jones; I Kirby; J Keeling; C K Ross; B A Larder; D I Stuart; D K Stammers
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

3.  Reactivation of thymidine kinase-defective herpes simplex virus is enhanced by nucleoside.

Authors:  R B Tenser; A Gaydos; K A Hay
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

4.  Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

Authors:  Jean Ruelle; François Roman; Anne-Thérèse Vandenbroucke; Christine Lambert; Katrien Fransen; Fedoua Echahidi; Denis Piérard; Chris Verhofstede; Kristel Van Laethem; Marie-Luce Delforge; Dolorès Vaira; Jean-Claude Schmit; Patrick Goubau
Journal:  BMC Infect Dis       Date:  2008-02-27       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.